Disc Medicine, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.discmedicine.com

Market Cap $1.74B
PE -17
Debt $NaN
Cash $192.87M
EV $NaN
FCF -$84.21M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$103.48M
EBIT	-$103.27M
ROE	-22%
ROA	-21%
FCF	-$84.21M
Equity	$467.96M
Growth Stability	1
PE	-16.79
PB	3.71
P/FCF	-20.64
Price/Cash	0.11
Equity CAGR	441%
Earnings Growth YoY	88%

Earnings Growth QoQ	1%
Equity CAGR 5Y	441%
Equity CAGR 3Y	86%
Market Cap	$1.74B
Assets	$495.15M
Cash	$192.87M
Shares Outstanding	26.81M
Working Capital	467.68M
Current Ratio	19.36
Shares Growth 3y	12%
Equity Growth QoQ	-4%
Equity Growth YoY	30%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of innovative therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The firm's pipeline includes investigational product candidates that affect heme biosynthesis and iron metabolism.

SEC Filings

Direct access to Disc Medicine, Inc. (IRON) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Disc Medicine, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Disc Medicine, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Disc Medicine, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Disc Medicine, Inc..

Years

Calculation mode

= -$842M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$84M	-$84M	-$84M	-$84M	-$84M	-$84M	-$84M	-$84M	-$84M	-$84M	-$84M	-$842M
DCF		-$77M	-$70M	-$63M	-$58M	-$52M	-$48M	-$43M	-$39M	-$36M	-$32M	-$325M
Value	-$842M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-
ROA	-49%	-23%	-21%	-21%
ROE	-58%	-27%	-22%	-22%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-
Debt over Equity	0	-	-	-
Growth Stability	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-
Earnings YoY growth	-	-35%	63%	-
Equity YoY growth	-	41%	95%	441%
FCF YoY growth	-	-29%	73%	-